- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07228247
Badanie fazy Ⅰ/Ⅱa preparatu HMPL-A251 u uczestników z zaawansowanymi lub przerzutowymi guzami litymi eksprymującymi HER2
Badanie fazy Ⅰ/Ⅱa mające na celu ocenę bezpieczeństwa, tolerancji, farmakokinetyki, immunogenności i wstępnej skuteczności preparatu HMPL-A251 u uczestników z zaawansowanymi lub przerzutowymi guzami litymi eksprymującymi HER2
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Przegląd badań
Szczegółowy opis
- To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
- To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Beijing, Chiny
- Rekrutacyjny
- Peking University First Hospital
-
Kontakt:
- Shikai Wu
- Numer telefonu: +86 18910715326
- E-mail: skywu4329@sina.com
-
Kontakt:
- Yu Fan
-
Changsha, Chiny
- Rekrutacyjny
- Hunan Cancer Hospital
-
Kontakt:
- Quchang Oyang
- Numer telefonu: 0731-89762161
- E-mail: Oyqc1969@126.com
-
Guangzhou, Chiny
- Rekrutacyjny
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Shusen Wang
- Numer telefonu: 020-87342693
- E-mail: Wangshus@susucc.org.cn
-
Hefei, Chiny
- Rekrutacyjny
- The First Affiliated Hospital of Anhui Medical University
-
Kontakt:
- Yingying Du
- Numer telefonu: 0551-65908511
- E-mail: duyy1980@126.com
-
Shanghai, Chiny
- Rekrutacyjny
- Fudan University Shanghai Cancer Center
-
Kontakt:
- Jian Zhang
-
Kontakt:
- Xiaohua Wu
- Numer telefonu: 18121299168
- E-mail: wu.xh@fudan.edu.cn
-
Shenyang, Chiny
- Rekrutacyjny
- The First Hospital of China Medical University
-
Kontakt:
- Funan Liu
- Numer telefonu: 13609877906
- E-mail: lfn_clinical@126.com
-
Zhengzhou, Chiny
- Rekrutacyjny
- Henan Cancer Hospital
-
Kontakt:
- Min Yan
- Numer telefonu: +86 157 1385 7388
- E-mail: ym200678@163.com
-
-
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rekrutacyjny
- SCRI HealthONE
-
Kontakt:
- Gerald Falchook
- Numer telefonu: 940-365-6217
- E-mail: bianca.reyes@scri.com
-
-
Florida
-
Plantation, Florida, Stany Zjednoczone, 33322
- Rekrutacyjny
- BRCR Global
-
Kontakt:
- Harshad Amin
- Numer telefonu: 561-447-0614
- E-mail: alejandrop@brcrglobal.com
-
Plantation, Florida, Stany Zjednoczone, 33322
- Rekrutacyjny
- Florida Clinical Trials Group LLC (Plantation)
-
Kontakt:
- Harshad Amin
- Numer telefonu: 772-297-3057
- E-mail: clinops@floridactg.com
-
Tamarac, Florida, Stany Zjednoczone, 33321
- Jeszcze nie rekrutacja
- Florida Clinical Trials Group LLC (Tamarac)
-
Kontakt:
- Chintan Ghandi
-
-
New Jersey
-
East Brunswick, New Jersey, Stany Zjednoczone, 08816
- Jeszcze nie rekrutacja
- START New Jersey
-
Kontakt:
- Bruno Fang
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Jeszcze nie rekrutacja
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Vicky Makker
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Rekrutacyjny
- Cleveland Clinic Taussig Cancer Center
-
Kontakt:
- WenWee Ma
- Numer telefonu: 216-559-9815
- E-mail: keaneyh@ccf.org
-
-
Washington
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Jeszcze nie rekrutacja
- Northwest Medical Specialties, PLLC
-
Kontakt:
- Jorge Chaves
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Histologically confirmed unresectable advanced or metastatic disease.
- Have at least one measurable lesion per RECIST v1.1;
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Weight ≥ 35 kg;
Exclusion Criteria:
- An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
- Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
- Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
- Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
- Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
- Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part A(Phase I)
Dose Escalation |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
|
Eksperymentalny: Part B(Phase IIa)
Dose Expansion/Dose Optimization |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Ramy czasowe: Approximately 12 months
|
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251 |
Approximately 12 months
|
|
Recommended doses for expansion (RDE)
Ramy czasowe: Approximately 12 months
|
The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data. |
Approximately 12 months
|
|
Overview of Treatment-emergent Adverse Events (TEAEs)
Ramy czasowe: Approximately 24 months
|
All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA). |
Approximately 24 months
|
|
Objective Response Rate (ORR)
Ramy czasowe: At least 6 weeks post dose of first participant up to approximately 24 months
|
ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1. |
At least 6 weeks post dose of first participant up to approximately 24 months
|
|
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Ramy czasowe: Approximately 12 months
|
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data. |
Approximately 12 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Disease control rate (DCR)
Ramy czasowe: Approximately 2 years
|
The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks. |
Approximately 2 years
|
|
Duration of response (DoR)
Ramy czasowe: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause. |
Approximately 2 years
|
|
Time to response (TTR)
Ramy czasowe: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR) |
Approximately 2 years
|
|
Progression-free survival (PFS)
Ramy czasowe: Approximately 2 years
|
The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first. |
Approximately 2 years
|
|
Overall survival (OS)
Ramy czasowe: Approximately 2 years
|
Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first. |
Approximately 2 years
|
|
Maximum plasma/serum concentration (Cmax)
Ramy czasowe: Cycle 1 and Cycle 3 (21-day cycle)
|
Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3. |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Time to maximum plasma/serum concentration (Tmax)
Ramy czasowe: Cycle 1 and Cycle 3 (21-day cycle)
|
Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609 |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Area under the plasma/serum concentration-time curve (AUC)
Ramy czasowe: Cycle 1 and Cycle 3 (21-day cycle)
|
Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Pre-dose plasma/serum concentration (Cmin)
Ramy czasowe: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609. |
Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
|
Immunogenicity of HMPL-A251
Ramy czasowe: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251 |
Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 2025-251-GLOB1
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .